Shift Bioscience Limited

Shift Bioscience Ltd, based in Cambridge, UK, is a small, active company founded seven years ago. With nine employees and £9,008,118 in assets, it operates from a real address within the Babraham Research Campus. The company is led by five directors and has one owner, Ives Daniel. It’s a regular importer of miscellaneous chemical products, with the latest import occurring in March 2025.

The company’s website reveals a focus on cell rejuvenation therapeutics, positioning itself at the intersection of biotechnology and artificial intelligence. Shift Bioscience has built datasets to uncover the hidden biology of cell aging, identifying genes that rejuvenate multiple cell types. It’s developing cell rejuvenation assets, including genes, siRNAs, and small molecules, targeting proaging genes, and invites partners to accelerate their development. The website highlights a world-class team of scientists bridging machine learning and cell biology, with leaders in virtual cells and cell aging clocks. The company also has a strong focus on leadership, with a chair, non-exec directors, and a translation advisor.

Financially, Shift Bioscience Ltd presents a mixed picture. While cash reserves increased dramatically by 380%, reaching £8.3 million, net assets declined by 65% to £14 million. Creditors rose significantly, increasing by 150% to £360,000, and bank borrowings also increased. The number of equity instruments granted to employees increased by 84%, suggesting a focus on talent acquisition. The company’s small size (meeting two of three conditions for being a small company) allows for agility, but the decrease in equity raises questions about its long-term financial health. The accounts are unaudited, as is typical for small companies.

Registered in England/Wales under the registration number 10793871, with a registered address at CB22 3AT, England, Cambridge, Cambridgeshire, Moneta (Building 280) Babraham Research Campus.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.